New York Life Investment Management LLC Reduces Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

New York Life Investment Management LLC lessened its stake in ImmunityBio, Inc. (NASDAQ:IBRXFree Report) by 13.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 195,629 shares of the company’s stock after selling 30,818 shares during the quarter. New York Life Investment Management LLC’s holdings in ImmunityBio were worth $331,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IBRX. Swiss National Bank boosted its holdings in shares of ImmunityBio by 9.2% in the 1st quarter. Swiss National Bank now owns 188,000 shares of the company’s stock valued at $1,055,000 after purchasing an additional 15,900 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of ImmunityBio by 28.5% in the 1st quarter. MetLife Investment Management LLC now owns 33,258 shares of the company’s stock valued at $187,000 after acquiring an additional 7,377 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of ImmunityBio by 3.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 493,059 shares of the company’s stock valued at $2,767,000 after acquiring an additional 16,672 shares during the period. Vident Investment Advisory LLC raised its stake in shares of ImmunityBio by 19.7% in the 1st quarter. Vident Investment Advisory LLC now owns 201,588 shares of the company’s stock valued at $1,131,000 after acquiring an additional 33,112 shares during the period. Finally, State Street Corp raised its stake in shares of ImmunityBio by 8.8% in the 1st quarter. State Street Corp now owns 6,760,306 shares of the company’s stock valued at $37,925,000 after acquiring an additional 544,929 shares during the period. Institutional investors and hedge funds own 8.60% of the company’s stock.

ImmunityBio Price Performance

Shares of IBRX stock opened at $4.74 on Tuesday. The company’s fifty day simple moving average is $4.08 and its 200-day simple moving average is $2.89. ImmunityBio, Inc. has a 52 week low of $1.21 and a 52 week high of $6.93.

About ImmunityBio

(Free Report)

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.

Featured Articles

Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRXFree Report).

Institutional Ownership by Quarter for ImmunityBio (NASDAQ:IBRX)

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.